Entries |
Document | Title | Date |
20080199519 | Production of Double-or Multi-Layered Microcapsules - The invention relates to a method for production of double- or multi-layered micro-capsules, comprising an inner microcapsule of cross-linked polymers and biological cells and one or more layers of cross-linked polymers without biological cells, which completely enclose(s) the inner microcapsule, whereby, in a first method step, single-layered microcapsules of cross-linked polymers with biological cells are produced and, in at least one further method step, at least one outer layer shell of cross-linked polymer is applied which contains no biological cells. | 08-21-2008 |
20080206323 | Soft Gelatin Capsules - The present invention relates to soft gelatin capsules characterized in that the shell includes a cyclodextrin and in that the filling material contains a liposoluble drug capable of forming a complex with said cyclodextrin for improving the solubility of the active ingredient upon disintegration of the soft gelatin capsule. | 08-28-2008 |
20080206324 | PELLETS HAVING AN ACTIVE COMPOUND MATRIX AND A POLYMER COATING, AND A PROCESS FOR THE PRODUCTION OF THE PELLETS - An active compound-containing pellet has a polymer coating of an anionic (meth)acrylate copolymer and a pharmaceutically active substance, embedded in a polymer matrix of one or more polymers, a particle size in the range from 300 to 1100 μm, a friability of at most 0.1%, measured using 200 g of pellets in a screening machine having a 200 μm screen, a screening diameter of 20 cm and 1.5 mm shaking amplitude at a shaking frequency of 50 l/sec for 10 min in the presence of six rubber cubes having a 1.8 cm edge length, with the proviso that the pellet releases no more than 10% of the active compound in a release test according to USP in artificial gastric juice at pH 1.2 after 120 min. | 08-28-2008 |
20080206325 | Encapsulated Active Ingredients, Methods of Preparation and Their Use - The present invention relates to particles that include an active ingredient that is encapsulated first by coacervation, and then by a glassy matrix. The glassy matrix includes 3-50 wt % of a hydrophobically modified starch, and 50-97 wt % of a starch hydrolysate. The particles are useful for encapsulating active ingredients intended for oral ingestion and may be added to food products. | 08-28-2008 |
20080248108 | MULTILAYERED POLYELECTROLYTE-BASED CAPSULES FOR CELL ENCAPSULATION AND DELIVERY OF THERAPEUTIC COMPOSITIONS - The present invention provides novel, biocompatible matrices for cell encapsulation and transplantation. It further provides methods for delivering agents to encapsulated cells and to the local environment of a host system. The invention also provides methods for targeting and manipulating particular cells and/or proteins of the host system. In a composition aspect of the invention, a composition including a collection of capsules is provided. The capsules comprise an inner core, and the inner core is covered by an outer shell composed of a positive polyelectrolyte and a negative polyelectrolyte. The inner core of the capsules contains at least one cell. | 10-09-2008 |
20080248109 | COMPOSITIONS AND METHODS FOR INHIBITING GASTRIC ACID SECRETION - The present invention is related to novel oral compositions comprising an irreversible gastric H | 10-09-2008 |
20080260820 | Oral dosage formulations of protease-resistant polypeptides - Oral dosage formulations of the protease-resistant therapeutic polypeptides are provided. The dosage formulations for administration per dosage per day or per week are higher than the subcutaneous dosage. Included among the oral dosage formulations are tablets and capsules, including enteric-coated forms. Methods for treatment or prevention of diseases or conditions that are treatable or preventable by the administration of such oral dosage formulations of protease-resistant polypeptides are provided. | 10-23-2008 |
20080260821 | Berry Preparations and Extracts - A method for deriving compositions having antioxidant and anti-inflammatory activity from berries is provided. The method results in a berry extract compositions having stable anthocyanin content. In one aspect, the method comprises exposing a berry to a solvent composition having a pH of from about 1 to about 4.5, and recovering a berry extract having a stabilized anthocyanin content. The berry may be a blackberry. A cryoprotectant may be added, to further stabilize the anthocyanin content. Compositions comprising the berry extract of the present invention, formulated for oral and/or topical administration, are provided also, including nutritional supplements, capsules, enteric-coated capsules, film-coated capsules, tablets, enteric-coated tablets, film-coated tablets, chewing gums, lotions, creams, mucoadhesive gels, vanishing lotions, vanishing creams, and the like. In yet another aspect, the present invention provides methods and compositions for treating inflammation, oxidative damage, or cancer in a mammal. | 10-23-2008 |
20080260822 | SYNTHESIS OF HUMAN SECRETORY IgA AND IgM AND THE FORMATION OF A MEDICAMENT THEREFROM - A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of | 10-23-2008 |
20080274176 | Pharmaceutical Lipid Compositions - The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilising amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and where the composition contains particles of at least one non-lamellar phase structure or forms particles of at least one non-lamellar phase structure when contacted with an aqueous fluid. The invention additionally relates to pharmaceutical formulations containing such compositions, methods for their formation and methods of treatment comprising their administration. | 11-06-2008 |
20080274177 | CONTROLLED RELEASE DOSAGE FORMS - The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups. | 11-06-2008 |
20080279931 | COMPOSITION FOR TREATMENT OF PAIN - The present invention is a composition delivering effective amounts of Glucosamine, Devils Claw, SAM, and NSAID in a single dosage unit. | 11-13-2008 |
20080311192 | Enteric-Coated Glucosinolates And Beta-Thioglucosidases - The present invention relates to a particulate composition comprising enteric-coated glucosinolate and beta-thioglucosidase particles. The present invention further provides a method of converting glucosinolate to isothiocyanate in the small intestine comprising orally administering to a subject an enteric-coated chemoprotectant precursor composition comprising enteric-coated glucosinolate and beta-thioglucosinodase particles. In another aspect, uncoated glucosinolate and beta-thioglucosinodase particles may be provided in an enteric-coated capsule. Preferably, the glucosinolate is glucoraphanin and the beta-thioglucosidase is myrosinase. The enteric coating targets the compound for release in the small intestine where beta-thioglucosinodase enzyme converts glucosinolate to chemoprotectant isothiocyanate. | 12-18-2008 |
20080317847 | HYDROSTATIC DELIVERY SYSTEM FOR CONTROLLED DELIVERY OF AGENT - The present invention provides a hydrostatic delivery system including a hydrostatic couple and an agent of interest. The hydrostatic couple includes at least one hydrodynamic fluid-imbibing polymer, and at least one hydrostatic pressure modulating agent. This delivery system has the ability to control the release of one or more agents of interest within a fluid environment following zero-order kinetics. | 12-25-2008 |
20090004264 | METHODS FOR TREATING AND AMELIORATING THE SYMPTONS OF INFLAMMATORY BOWEL DISEASES - This invention relates to methods of treatment of inflammatory bowel disease, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the methods of the invention are disclosed. | 01-01-2009 |
20090011012 | FATTY ACID COMPOSITIONS AND METHODS OF USE - The invention relates to highly concentrated DHA and EPA formulations in a soft gel capsule. A capsule may contain at least 80% omega-3 fatty acids, salts or derivatives thereof, where EPA and DHA are present in relative amounts of greater than or equal to 3:1 or less than or equal to 1:3, and constitute at least 75% to greater than 95% of the total fatty acids present in the capsule. Capsules of the invention may be provided in a blister package so as to provide clean and protected oils that are easy to travel with. Compliance is improved with one-pill-a-day dosing and the days of the week imprinted on the foil packing. Anitoxidant protection may be provided by rosemary and vitamin C. The invention also provides a methods of treatment, modulation or prophalaxis of coronary disease, altering serum LDL-cholesterol and/or HDL-cholesterol, lowering serum triglycerides, lowering blood pressure, pulse rate, altering the activity of the blood coagulation factor VII complex, mild hypertension, protection from cyclosporine toxicity in kidney transplant, rheumatoid arthritis, development and progression of retinopathy, hypertriglyceridemia, and neurological disorders in a subject. | 01-08-2009 |
20090035371 | TABLET WITH REMEDIAL COMPOSITION AND METHODS FOR TREATING MEDICAL DISORDERS AND AILMENTS - The invention discloses a pharmaceutical composition useful for treatment and prevention of medical disorders and ailments. The aforesaid composition comprises active ingredients comprising; Turmeric extract, Turmeric powder, optionally, Selenium or source of Selenium, especially Selenomethionine, optionally, Green tea extract. The pharmaceutical composition further comprises enteric coating encapsulating the same. The disclosed pharmaceutical composition is especially adapted for treatment of inflammatory bowel disease (IBD) and colorectal cancer (CRC). | 02-05-2009 |
20090068261 | ORAL RAPID RELEASE PHARMACEUTICAL FORMULATION FOR PYRIDYLMETHYLSULFINYL-BENZIMIDAZOLES - The invention relates to solid oral pharmaceutical compositions in the form of pellets, mini-tablets, tablets, or capsules, comprising an optionally substituted 2-(pyridylmethylsulfinyl)-1H-benzimidazole, for example esomeprazole, and carrageenan, and optionally one or more excipients. Surprisingly, it has been found that these compositions are stable and rapidly release the active ingredient. The pellets or mini-tablets may be coated as such, or filled in capsules or pressed into tablets, with a polymer, which dissolves only at a pH value of 5 or higher, optionally over a stabilizing intermediate layer. | 03-12-2009 |
20090092668 | ACETAMINOPHEN FORMULATION FOR JOINT PAIN RELIEF - The invention relates generally to a formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for joint pain relief. The formulation may comprise supplements such as glucosamine, hyaluronic acid and methylsulfonylmethane (MSM) and acetaminophen for acute joint pain. The invention also encompasses methods for joint pain relief with the formulation described herein. | 04-09-2009 |
20090117180 | STABLE DIGESTIVE ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 9% or less or 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 25%, about 20%, about 15% or about 10% after six months of accelerated stability testing and the titer level of a viral contaminant present in the pancreatin is at least about 1000 times less than the titer level of the viral contaminant present in a preparation from which the pancreatin is obtained. | 05-07-2009 |
20090123537 | ORAL DOSAGE FORM OF CEFTRIAXONE AND METHODS OF USE - The present invention contemplates a novel oral dosage form for the intestinal delivery of ceftriaxone sodium. The oral dosage form inhibits enteric degradation of the therapeutic compound by encapsulation within an inner core region and having an outer shell, preventing its dissolution until reaching the small intestine. Furthermore, the enzymatic degradation of the compound is substantially inhibited until absorption at the intestinal mucosa. | 05-14-2009 |
20090136567 | Adhesin-enterotoxin chimera based immunongenic composition against enterotoxigenic Escherichia Coli - The inventive subject matter relates to an immunogenic composition composed of a chimeric molecule including a conformationally stable adhesin from | 05-28-2009 |
20090148519 | PULSED-RELEASE PREPARATION HAVING IMPROVED DISINTEGRATION PROPERTIES IN VIVO - An object of the present invention is to provide a pulsed-release preparation that achieves pulsed-release by coating the exterior of a core that contains a physiologically active substance and a disintegrant, with a controlled-release coating that contains a water-insoluble polymer and an enteric polymer, or a water-insoluble polymer and a water-soluble polymer, wherein a satisfactory pulsed-release can be achieved without increasing the amount of disintegrant in the core, in particular even in the low-water environment in the lower part of the digestive tract. The present invention provides a pulsed-release preparation comprising: 1) a core containing a physiologically active substance and a disintegrant; 2) an enteric coating that covers the core; and 3) a controlled-release coating that covers the enteric coating applied on the core and that contains a water-insoluble polymer and an enteric polymer or water-soluble polymer. | 06-11-2009 |
20090252789 | ONE STEP SPRAY-DRYING PROCESS - Capsules encapsulating an active or functional ingredient are obtainable by a process in which a feed that includes this ingredient is dispersed in the form of drops in a spraying tower and exposed to a temperature in the range of −20° C. to 500° C. In the tower, a cloud of suspended powdering agent provides a coating and prevents the capsules from sticking together and a reactant is provided to react with a polymer or film-forming carrier of the active ingredient so as to modify the water solution properties of the capsule walls. | 10-08-2009 |
20090263479 | FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention relates to a pharmaceutical oral dosage form containing a poorly permeable active pharmaceutical ingredient and at least one permeability improving substance, wherein the permeability improving substance is thermostably embedded in a water-soluble matrix of a water soluble carrier, and to thermostable formulations which can be used to improve bioavailability. | 10-22-2009 |
20090274755 | Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals - The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylthio)-1H-benzimidazole to its sulfoxide: 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl) methyl)methylsulfinyl)-1H-benzimidazole comprising: reacting the thioether with: 1) a transition metal catalyst; and, 2) an oxygen source; wherein the thioether is oxidized to a sulfoxide and wherein one of either the R and S enantiomers is formed to an enantiomeric excess. | 11-05-2009 |
20090280169 | Compositions of peptides and processes of preparation thereof - The present invention provides composition of comprising a therapeutically effective amount of at least one peptide, polypeptide, analog or derivative thereof and a sufficient amount of at least one stabilizing agent to improve the stability of the peptide, polypeptide, an analog or derivative thereof, wherein at least one stabilizing agent is a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent. The method for preparation of a composition of a peptide, polypeptide, protein, an analog and/or derivative thereof is also provided. The process comprises mixing the peptide, polypeptide, protein, an analog or derivative thereof with a sufficient amount of at least one stabilizing agents to improve the stability of the peptide, polypeptide, protein, an analog or derivative thereof, and the agent is a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent. | 11-12-2009 |
20090280170 | Compositions of GnRH related compounds and processes of preparation - The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent. | 11-12-2009 |
20090291134 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES - The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases. Specifically, the present invention relates to the composition comprising endoxifen in the treatment of bipolar disorder, schizophrenia, multiple sclerosis (MS), Alzheimer disease, Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and/or epilepsy by administrating formulations or compositions comprising an effective amount of endoxifen. | 11-26-2009 |
20100021538 | PHARMACEUTICAL COMPOSITIONS CONTAINING HEPARIN DERIVATIVES - An oral pharmaceutical composition for anticoagulation of blood includes a conjugate of an anticoagulation polysaccharide, such as heparin, covalently bonded to a hydrophobic agent wherein the conjugate is mixed with a solubilizer for inhibiting self-aggregation of the conjugate into nanoparticles. The composition can be coated, formed into tablets, or placed in capsules. Methods of making these oral formulations are also described. | 01-28-2010 |
20100028422 | Pharmaceutical Compositions and Methods for Treating or Preventing Oxalate-Related Disease - The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing pharmaceutical compositions to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions. | 02-04-2010 |
20100028423 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism. | 02-04-2010 |
20100028424 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism. | 02-04-2010 |
20100034875 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism. | 02-11-2010 |
20100055178 | ENTERIC-COATED CREATINE COMPOSITIONS AND METHODS OF USE THEREOF - Compositions and methods are provided for supplementing dietary creatine and facilitating absorption of creatine, comprising an enteric-coated creatine pharmaceutical formulation that may be provided as a tablet, capsules, pellet, and microbead in the form of creatine monohydrate, creatine phosphate, creatine cytrate, creatine pyruvate, or creatine ethyl ester. | 03-04-2010 |
20100062059 | S-Nitrosothiols Containing Composition for the Treatment of Fatty Liver Diseases, Obesity and Other Diseases Associated with the Metabolic Syndrome and the Use of Such Compositions - The present invention refers to pharmaceutical compositions containing S-nitrosothiols as active principle. The referred compositions are intended for the treatment of the fatty liver disease and other diseases associated with the metabolic syndrome. The composition is administered either orally or rectally. | 03-11-2010 |
20100112048 | Dosage Regimen and Medicament For Reducing Risk of Onset or Progression of Dementia by Administration of Specific Vitamins and Nsaid - The present invention relates to a synergistic combination for preventing the onset and/or progression of dementia or Alzheimer's disease in individuals at increased risk thereof for example because of family history, genetic factors, and/or environmental factors. This combination comprises synergistically effective amounts of vitamin C, vitamin E, DHA and at least one NSAID such as ibuprofen. | 05-06-2010 |
20100112049 | PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRATE AND METHOD FOR THE PREPARATION THEREOF - Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions. | 05-06-2010 |
20100143463 | BACTERIAL DIVERSITY - Use of one strain of | 06-10-2010 |
20100143464 | CROSS-LINKED ALGINATE-POLYALKYLENE GLYCOL POLYMER COATINGS FOR ENCAPSULATION AND METHODS OF MAKING THE SAME - A biocompatible capsule comprising a biological material encapsulated by a covalently stabilized coating and a method of making the same are disclosed. The biological material can be a material selected from the group consisting of cells, such as islets of Langerhans, pharmaceuticals, and biological agents. The coating can be formed by reacting an alginate-[polyalkylene glycol (PAG)-X | 06-10-2010 |
20100172976 | METHODS AND COMPOSITIONS FOR INHIBITING THE FUNCTION OF POLYNUCLEOTIDE SEQUENCES - A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell. In methods of treatment of prophylaxis of virus infections, other pathogenic infections or certain cancers, these compositions are administered in amounts effective to reduce or inhibit the function of the target polynucleotide sequence, which can be of pathogenic origin or produced in response to a tumor or other cancer, among other sources. | 07-08-2010 |
20100172977 | Abscisic acid against cancer - ABSCISIC Acid (ABA) a naturally occurring plant hormone has been identified in this invention with potent properties to fight cancer. ABA is able to produce a hyperpolarization condition on plasma membrane through a decrease of intracellular Na+ and K+. Such phenomenon is produced in cancer cells by mediation of ion channel and activation of the signaling g-protein pathway. ABA aborting sustained depolarization in malignant tissue will produce a change in the configurational state of cell from a damage to a normal state. additionally, a positive polarization of hCG outer layer accomplished through a removal of electrons will permit immune system cells coming close to cancer cells for destruction. | 07-08-2010 |
20100183714 | GASTRORESISTANT PHARMACEUTICAL DOSAGE FORM COMPRISING N-(2-(2- PHTHALIMIDOETHOXY)-ACETYL)-L-ALANYL-D-GLUTAMIC ACID (LK-423) - The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed. | 07-22-2010 |
20100196470 | DEVICE AND METHOD FOR REDUCING CALORIE INTAKE - Devices and methods for substantially reducing the caloric efficiency of the digestive tract by capturing food being digested in the stomach | 08-05-2010 |
20100209502 | Treatments Which Alleviate Functional Glycosylated Leptin Transport Factor for Controlling Weight and Obesity - Methods and compounds for treating obesity and inducing weight loss use a functional, glycosylated leptin transport factor (LTF) polypeptide, referred to as fn/glyLTF. An unstable defective version of the LTF protein, referred to herein as def/LTF, is present in freshly-drawn blood from obese animals or people; it is degraded rapidly in circulating blood. In people with normal body weight, fn/glyLTF stabilizes and protects leptin, a hormone with powerful effects on fat metabolism and body mass. LTF apparently is the same protein previously recognized as a soluble truncated fragment of the obesity receptor (Ob-R) protein, referred to in the prior art as Ob-Re, or sOb-R. In humans with normal body weight, fn/glyLTF has a weight of about 145 kD, compared to a polypeptide-only weight of about 93 kD. defLTF has a substantially lower molecular weight, and tests using deglycosylating enzymes indicate that it is not glycosylated to the same level as fn/glyLTF. Treatment methods include: (1) elevating concentrations of fn/glyLTF in circulating blood, by means such as intravenous injection or sustained-release implants, or by gene therapy; (2) suppressing enzymatic deglycosylation in circulating blood, such as by extracorporeal removal of deglycosylating enzymes; and, (3) providing “surrogate” forms of fn/glyLTF. Diagnostic kits are also disclosed, for measuring both fn/glyLTF and def/LTF in animals and people suffering from obesity. | 08-19-2010 |
20100221329 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE - The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative. | 09-02-2010 |
20100221330 | BUOYANT FORMULATIONS OF BETAINE - An oral control release formulation for releasing at least one betaine after oral administration to a human, said formulation comprising at least one pharmaceutically acceptable means ensuring an at least partial floating of the formulation releasing at least one betaine in the gastro-intestinal tractus. | 09-02-2010 |
20100255088 | Method for delivering a combination of resveratrol and aspirin for use in treatment and prevention of vascular disease - A method for delivering a composition for use in treatment and prevention of vascular disease by providing a vehicle for delivery of the composition to an individual, wherein the composition contains a combination of aspirin and resveratrol; administering the vehicle to the mouth of the individual, wherein the vehicle melts at the body temperature of the individual such that the aspirin and resveratrol is absorbed thru the oral mucosa and delivered directly into the inidvidual's bloodstream; and a related melting capsule comprised of a material that has the same melting point as the human body temperature and includes aspirin in the range of 81 to 325 mg and resveratrol in the range of 10 to 300 mg. | 10-07-2010 |
20100266685 | Seamless Coated Spherical Filled Capsules - Described is a spherical coated capsule comprising (a) a coating-free capsule having (i) a liquid or viscous core and (ii) a solid shell surrounding this core, and (b) a seamless, solid coating surrounding said coating-free capsule, wherein the diameter of the spherical coated capsule is in the greater than 9 mm, the solid coating comprises at least one sugar or sugar-alcohol in an amount in the range of 30-90% (m/m), based on the total mass of the coated capsule, the diameter of the coating-free capsule is in the range of 5-10 mm, the thickness of the shell of said coating-free capsule is in the range of 30-200 μm, the ratio of shell thickness diameter of said coating-free capsule is in the range of 0.004-0.04, the shell of said coating-free capsule contains 70-90% (m/m) gelatine or alginate and 10-30% (m/m) plasticiser, based on the dry mass of said shell, and the core has a flavouring content in the range of 1-100% (m/m), based on the total mass of the core. Further described is a method for preparing such capsule. | 10-21-2010 |
20100272799 | COATING TECHNOLOGY TO PRODUCE A COMBINATION SOLID DOSAGE FORM - The present invention claims the usage of coating technology to produce multi-segmented pharmaceutical dosage forms for a combination drug therapy. The core matrix containing a drug is coated with drug containing solutions or suspensions. The separation of different drugs in the core and various coating segments prevents drug-drug interaction and improve drug stability, provide desired release rates for different drugs in the dosage form. The dosage form may release drugs in different parts of the gastrointestinal tract. | 10-28-2010 |
20100285121 | Capsule Formulation - The present invention provides the following capsule preparation, which is superior in dissolution property and the like of a pharmaceutically active ingredient and contains liquid and solid pharmaceutically active ingredients: a seamless capsule containing liquid and solid pharmaceutically active ingredients, wherein the liquid pharmaceutically active ingredient is encapsulated in the form of a liquid pharmaceutical composition, and the solid pharmaceutically active ingredient is dispersed in a capsule shell layer. | 11-11-2010 |
20100303904 | TABLET WITH REMEDIAL COMPOSITION AND METHODS FOR TREATING MEDICAL DISORDERS AND AILMENTS - The invention discloses a pharmaceutical composition useful for treatment and prevention of medical disorders and ailments. The aforesaid composition comprises active ingredients comprising; Turmeric extract, Turmeric powder, Selenium or source of Selenium, especially Selenomethionine, and Green tea extract. The disclosed pharmaceutical composition is especially adapted for treatment of inflammatory bowel disease (IBD) and colorectal cancer (CRC). | 12-02-2010 |
20110002986 | Stable Shellac Enteric Coating Formulation for Nutraceutical and Pharmaceutical Dosage Forms - The present invention relates to formulations for use as enteric coatings. More particularly, the present invention relates to a formulation comprising a blend of food grade ingredients that can be readily dispersed in water. This dispersion exhibits low viscosity and can easily be coated onto solid dosage forms through spraying and the like to provide an enteric coating on the solid dosage form. | 01-06-2011 |
20110008427 | Microcapsules and Methods - The present invention relates to microcapsules and methods for the production of microcapsules using sterically stabilized colloidal particles wherein the microcapsule comprises a core and a shell and wherein the shell comprises a layer of sterically stabilised colloidal particles and is characterized by the fact that the microcapsule has a mean size from 1 to 100 microns. | 01-13-2011 |
20110020441 | USE OF 5-AMINOLEVULINIC ACID AND DERIVATIVES IN A SOLID FORM FOR PHOTODYNAMIC TREATMENT AND DIAGNOSIS - The present invention relates to the use of a photosensitiser which is 5-ALA or a precursor or derivative thereof (e.g. an ALA ester), in the manufacture of a pharmaceutical product for use in the photodynamic treatment or diagnosis of cancer, an infection associated with cancer, or in the treatment or diagnosis of a non-cancerous condition, wherein said pharmaceutical product is in the form of a solid. The invention also relates to solid pharmaceutical products for use in such methods, e.g. suppositories, pessaries, tablets, pellets and capsules which comprise 5-ALA or a precursor or derivative thereof (e.g. an ALA ester) and at least one pharmaceutically acceptable carrier or excipient. Such products are particularly suitable for use in the photodynamic treatment or diagnosis of cancerous or non-cancerous conditions in the lower part of the gastrointestinal system or in the female reproductive system, e.g. in the treatment or diagnosis of colorectal cancer or cervical cancer. | 01-27-2011 |
20110020442 | Taste Masked Oral Composition of Telithromycin - The invention relates to an oral compositions comprising telithromycin that have taste masking properties, a process for the preparation thereof, and methods of using the composition. | 01-27-2011 |
20110081414 | Method for Encapsulation of Orally Ingested Materials to Alter the Site of Digestion, Site of Action, or Stability - Comestible materials encapsulated by a film-forming composition including a plant protein source and methods of forming the same are provided. The film-forming composition affects the site of digestion of the comestible material within the digestive tract of an animal or a human thereby allowing the material to be most effectively utilized by the body. Also, the film-forming compositions may be used to enhance the stability of the encapsulated material and prevent undesired interaction with other components of a mixture. | 04-07-2011 |
20110086095 | Bioadhesive Polymers - Polymers and compositions, collectively “bioadhesive materials”, with improved bioadhesive properties have been developed. One or more compounds comprising: a) an aromatic moiety comprising two or more hydroxyl substituents, methoxy substituents, substituents hydrolyzable to hydroxyl substituents, or a combination thereof, and b) a primary or secondary amino moiety are either covalently attached to a polymer or are physically mixed with a polymer to form a bioadhesive material. These bioadhesive materials can be used, for example, to fabricate new drug delivery or diagnostic systems with increased residence time at tissue surfaces, and consequently increase the bioavailability of a drug or a diagnostic agent. | 04-14-2011 |
20110091543 | ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS - Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, but does exhibit binding to iron and/or the transferrin receptor. Such fusion proteins may be administered orally. | 04-21-2011 |
20110097399 | FAST DISSOLVING/DISINTEGRATING COATING COMPOSITIONS - A pharmaceutical composition for oral administration comprising a core and a film coating on the core that exhibits enhanced disintegration characteristics is disclosed. The film coating comprises a film forming polymer, an organic solvent, a super-disintegrant and, optionally, an acid labile material. | 04-28-2011 |
20110111023 | PREVENTION OF TYPE 1 DIABETES BY ADMINISTRATION OF GLIADIN - The invention herein is related to intranasal or other mucosal administration of gliadin, or parts thereof, to prevent the development of type 1 diabetes. This environmental antigen, which may have etiological role in the development of diabetes in genetically predisposed individuals, has been successfully applied in the prevention of disease. | 05-12-2011 |
20110123614 | Oral Dosage Forms for Delivery of Therapeutic Agents - Oral dosage forms for the delivery of therapeutic agents include mechanical fasteners for engaging tissue of the gastrointestinal tract. | 05-26-2011 |
20110142927 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one anti-hemophilic factor or bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery. | 06-16-2011 |
20110150992 | QUININE FORMULATIONS, METHOD OF MAKING, AND METHOD OF USE THEREOF - Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or no bitter taste. The dosage forms provide immediate release in vitro and in vivo. | 06-23-2011 |
20110182986 | CONTROLLED RELEASE COMPOSITION - An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract. | 07-28-2011 |
20110206764 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS - A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided. | 08-25-2011 |
20110206765 | Non-Typeable Haemophilus Influenzae Vaccines and Their Uses - Provided are non-typeable | 08-25-2011 |
20110223248 | METHODS AND COMPOSITIONS FOR TREATING LACTOSE INTOLERANCE - The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a lactose composition optionally in combination with effective amount of a probiotic, prebiotic, or both. | 09-15-2011 |
20110244038 | BERRY PREPARATIONS AND EXTRACTS - Compositions having antioxidant and anti-inflammatory activity, and methods for providing such compositions, are disclosed. In one aspect, the compositions are derived by exposing a berry to an acidic solvent composition, adding a cryoprotectant, and recovering a berry extract having a stabilized anthocyanin content. Compositions comprising the stabilized anthocyanin-containing berry extract, formulated for oral and/or topical administration, are provided also. | 10-06-2011 |
20110274750 | ENTERIC FORMULATION OF DULOXETINE AND ITS CORE AND PREPRATION METHOD - An enteric formulation of duloxetine, its core and preparing method thereof are disclosed. The core comprises duloxetine or its salt and pharmaceutically acceptable excipients. The excipients include water-soluble hot melt materials selected from PEG, poloxamer, polyoxyl (40) stearate or their mixture. Based on the total weight of the core, the amount of water-soluble hot melt materials is 10%˜40% and the amount of duloxetine or its salt is 15˜60%. The core material is prepared by hot melt process. The enteric formulation comprises the core, a separating layer and an enteric layer. | 11-10-2011 |
20110300213 | Oral formulations of bipolar trans carotenoids - The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a bipolar trans carotenoid, ii) a cyclodextrin, and iii) a coating. The invention also relates to preparation of such formulations and their uses. | 12-08-2011 |
20110305755 | METHOD OF ADDING BOTANICAL AGENTS/DIETARY SUPPLEMENTS TO PHARMACEUTICAL AGENTS IN A PHARMACOTHERAPEUTIC REGIMEN - A method for administering an active pharmaceutical agent (APA) is provided that includes the steps of: a) providing a medicine having a dose of at least one APA and at least one active botanical agent (ABA) or dietary supplement; and b) dosing the APA within the medicine such that within each subsequent dose of the medicine, the amount of the APA decreases and the amount of the ABA increases, or remains the same, or decreases relative to an earlier amount. A trace of the APA may or may not remain in the pill toward the end of medicine application. | 12-15-2011 |
20110311621 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF DELVERY - The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent (such as CCK-8, octreotide), at least one salt of a medium chain fatty acid, a matrix forming polymer and a hydrophobic(lipophilic) medium. A surfactant may be included in the suspension. The pharmaceutical compositions may be formulated in a capsule or tablet for oral delivery. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. | 12-22-2011 |
20110311622 | METHOD FOR ADDING SENSORY CONDITIONING CUES IN A PHARMACOTHERAPEUTIC REGIMEN - A method for administering pharmaceutical agents to a subject is provided. The method includes the steps of: a) providing a course of treatment for a subject, which course includes periodically administering an amount of medicine to the subject, which amount of medicine includes a dose of at least one active pharmacological agent (APA) and an amount of at least one non-active pharmacological agent (NPA), which NPA provides at least one non-visual sensory cue; and b) varying the dosage amount of the APA within the periodically administered amount of medicine, while the amount of the NPA contained within each periodically administered amount of medicine is provided at a level that maintains the sensory cue at a substantially constant level. | 12-22-2011 |
20120003307 | LEVETIRACETAM CONTROLLED RELEASE COMPOSITION - The present invention is concerned with controlled release compositions for oral administration comprising levetiracetam; and with processes of preparing such controlled release compositions. | 01-05-2012 |
20120009256 | Treatment Including Prebiotic Composition for use with Probiotics - Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of | 01-12-2012 |
20120034299 | COMPOSITIONS FOR THE TREATMENT OF GLUTEN INTOLERANCE AND USES THEREOF - The present invention provides compositions for use in the prophylaxis or treatment of a condition arising from gluten intolerance, the compositions including at least partially purified caricain (or a biologically active fragment, analogue or variant thereof) alone or in combination with other suitable enzymes including bromelain, and/or an intestinal extract, as herein described. The present invention also provides methods of using such compositions for the prophylaxis or treatment of a condition arising from gluten intolerance. | 02-09-2012 |
20120045509 | MODIFIED RELEASE COMPOSITIONS FOR DPP-IV INHIBITORS - The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor. | 02-23-2012 |
20120064156 | Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs - The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. | 03-15-2012 |
20120082720 | Compositions For Treating Chronic Viral Infections - The present invention describes dietary compositions and methods of using such compositions to treat chronic viral infections, including hepatitis B and hepatitis C infections. | 04-05-2012 |
20120082721 | Enteric coating - The present invention refers to a dosage form comprising an enteric coating in a specific amount, and to the use of enteric coating compositions for preparing a dosage form. Furthermore, the present invention also relates to a process for the preparation of a solid oral dosage form. | 04-05-2012 |
20120087977 | AQUEOUS CARBONATED MEDIUM CONTAINING AN AMINO(METH)ACRYLATE POLYMER OR COPOLYMER - The invention relates to an aqueous medium containing an amino(meth)acrylate polymer or copolymer which is not soluble in demineralised water, characterized in that the medium has a content of an aqueous phase of at least 60% by weight and a content of up to 40% by weight of solids comprising the amino(meth)acrylate polymer or copolymer, whereby the aqueous phase is charged by a sufficient amount of carbon dioxide that effects the amino(meth)acrylate polymer or copolymer to be present in solute form in the medium. The aqueous medium may be used beneficially as a coating or binding solution for the spray coating or binding of pharmaceutical compositions or nutraceutical compositions or cosmetical compositions. | 04-12-2012 |
20120093926 | GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL FORMULATION COMPRISING ONE OR MORE SALTS OF ALGINIC ACID - The invention relates to a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the release of the pharmaceutical or nutraceutical active ingredient is not more than 15% under in-vitro conditions at pH 1.2 for 2 hours in medium according to USP with and without the addition of 40% (v/v) ethanol, wherein the gastric resistant coating layer comprises 10 to 100% by weight of one or more salts of alginic acid with a viscosity of 30 to 720 cP of a 1% aqueous solution | 04-19-2012 |
20120100210 | COMPOSITION FOR THE ADMINISTRATION OF POLYMERIC DRUGS - Provided are improvements in and relating to pharmaceutical compositions for oral administration of polymeric biological drug substances and to methods of treatment using such compositions. In particular, an oral and/or mucosal pharmaceutical composition is provided, said composition comprising an enteric-coated drug substance, and also comprising an enteric-coated oligouronate, wherein said drug substance is a polymeric biological drug substance. | 04-26-2012 |
20120114751 | PHARMACEUTICAL COMPOSITION FOR TREATING HCV INFECTIONS - The present invention relates to a granular pharmaceutical composition comprising an HCV protease inhibitor and at least one poloxamer. | 05-10-2012 |
20120156290 | PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE - Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included. | 06-21-2012 |
20120195964 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF - The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and an enteric coating. | 08-02-2012 |
20120207826 | NOVEL PARASITE THERAPY - There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate. There is also disclosed herein a method for treating extracellular parasitic infections in a vertebrate in need of said treatment, wherein said treatment comprises administering to said vertebrate a therapeutically effective amount of (i) a composition comprising a quinolone or fluoroquinolone together with a pharmaceutically acceptable carrier or (ii) a composition of the invention or (iii) a combination of at least one quinolone or fluoroquinolone optionally together with at least one tetracycline, iodoquinol, an azole or imidazole; or (iv) a combination of at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate. | 08-16-2012 |
20120207827 | DIMETHYL SULFOXIDE (DMSO) AND METHYLSULFONYLMETHANE (MSM) FORMULATIONS TO TREAT OSTEOARTHRITIS - Embodiments of the invention relate generally to the use of formulations comprising DMSO and MSM to treat arthritis (such as osteoarthritis), pain, inflammation, and/or degeneration. DMSO and MSM formulations are administered orally and/or topically in several embodiments and provide effective treatment of both chronic and acute symptoms of arthritis (e.g., osteoarthritis), pain, inflammation, and/or degeneration. Solid forms of DMSO are provided in several embodiments. | 08-16-2012 |
20120213848 | Treatment of Infection Using Single Chain Antibody Gene Therapy - A method for treating HIV and other intra-cellular parasites and toxins using intrabodies delivered to leukocytes. | 08-23-2012 |
20120219620 | SCF Extract Containing Cardiac Glycoside - A supercritical fluid (SCF) extract of a cardiac glycoside-containing plant mass is provided. The extract can be included in a pharmaceutical composition containing an extract-solubilizing amount of solubilizer. Oleandrin is included within the extract when a cardiac glycoside-containing plant, such as | 08-30-2012 |
20120231074 | PHARMACEUTICAL SOLID DOSAGE FORM - The present invention is directed to a solid dosage form comprising (i) a core comprising a benzimidazole; (ii) a separating layer comprising a water soluble polymer and glyceryl monostearate; and (iii) an enteric coating. | 09-13-2012 |
20120237599 | ENTERICALLY COATED CYSTEAMINE, CYSTAMINE AND DERIVATIVES THEREOF - The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects. | 09-20-2012 |
20120269891 | CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG - Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration. | 10-25-2012 |
20120315329 | SILOXANE SURFACE-MODIFIED HYDROGEL AND HYDROGEL MICROPARTICLE COMPOSITIONS - Embodiments of the present invention relate generally to siloxane surface-modified hydrogel microparticles and pastes, methods for their preparation, and uses thereof for delivery of personal care and healthcare active ingredients, as well as agricultural active ingredients. | 12-13-2012 |
20120321709 | COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF - Disclosed are a complex formulation for oral administration comprising probiotic formulation and 5-HT4 receptor agonist, and a method for the preparation thereof. | 12-20-2012 |
20120328698 | COATING METHOD - The present invention concerns a method for coating granules comprising mesalazine, with a coating mixture comprising two polymers, polymer I and polymer II; said polymer I being selected to allow formation of a closing membrane around said granules in the absence of said polymer II, and said polymer II being selected to act as a water-soluble pore former in said coating mixture; wherein a) the amount of polymer I is adjusted to provide a closing membrane in the absence of polymer II, and b) the amount of polymer II in said coating mixture is adjusted to obtain coated granules which exhibit controlled release of mesalazine. The invention further concerns a product obtainable by the coating method. | 12-27-2012 |
20130017260 | ORAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF HUMAN CANITIES - The present application relates generally to oral pharmaceutical formulations for the treatment of human canities. | 01-17-2013 |
20130017261 | USE OF LACTOBACILLUS FOR TREATMENT OF VIRUS INFECTIONS - The present invention relates to the use of at least one strain of probiotic bacteria selected from | 01-17-2013 |
20130059001 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF THE SYMPTOMS OF ADDICTION AND METHOD OF DIAGNOSING SAME - A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed. | 03-07-2013 |
20130078305 | Pharmaceutical Compositions For The Coordinated Delivery Of NSAIDs - The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. | 03-28-2013 |
20130089606 | METHODS AND COMPOSITIONS FOR ORAL PHARMACEUTICAL THERAPY - It now has been found that oral administration of pharmaceutical agents, including N-methylol transfer agents such as Taurolidine may be used to provide efficacious blood plasma concentration of the agents for treatment of diseases by providing release of the active agent into the duodenum or jejunum of a patient and/or at a pH of about 5.4 to about 6.5. Embodiments of the invention therefore provide oral dosage forms, compositions and methods for administration of pharmaceutical agents to the duodenum or jejunum of a patient, and/or which release at a pH of about 5.4 to about 6.5. | 04-11-2013 |
20130101669 | LOGICAL ENZYME TRIGGERED (LET) LAYER-BY-LAYER NANOCAPSULES FOR DRUG DELIVERY SYSTEM - Nanocapsule compositions comprising a calcium carbonate core surrounded by a bilayer or bilayers of polystyrene sulfonate and poly(allylamine hydrochloride). The poly(allylamine hydrochloride) is conjugate to a substrate, wherein the substrate is capable of being acted upon (for example cleaved) by a biomarker or enzyme associated with a disease state of interest. The nanocapsule compositions may be administered to an animal, for example a human, for the treatment of a disease state. | 04-25-2013 |
20130115285 | ENTERIC COATING COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - An enteric coating composition including about 0.01% to about 10% resin and about 0.01% to about 10% polymer. The enteric coating composition may be applied to a substrate, such as a pharmaceutical, nutraceutical, fruit, vegetable, agricultural product, or industrial product, to form an enteric coating on the substrate. Also provided is a multiple-component system having a first component including a resin and a second component including a polymer, wherein mixing the first component and the second component forms an enteric coating composition having about 0.01% to about 10% resin and about 0.01% to about 10% polymer. Methods for coating a substrate with the enteric coating compositions are also provided. | 05-09-2013 |
20130115286 | ORAL ADMINISTRATION FORMS FOR CONTROLLED RELEASE OF RIFAMPICIN FOR THE TREATMENT OF BACTERIAL INFECTIONS AND INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT - Oral administration forms are described for the controlled release of an antibiotic selected from the group consisting of rifampicin, rifabutin, rifapentine, rifalazil and mixtures thereof, for treating bacterial infections of the gastrointestinal tract, in particular travellers' diarrhoea, hepatic encephalopathy, ulcerative colitis, irritable bowel syndrome (IBS), Crohn's disease, and IBD (inflammatory bowel disease) in general. Moreover, said oral administration forms allow reduction of the amounts of antibiotic to be taken, with respect to the known administration forms and without reaching blood concentrations such as to select resistant strains of tuberculosis mycobacteria. | 05-09-2013 |
20130142872 | EMP2: Ethyl-Methyl, di Methyl, tri Methyl Pyruvate Acid Esters: A Tool for Regulating HbA1c and a Riboswitch Activator - The invention is a novel series of compounds represented by general formula, its analogs, tautomeric forms, stereoisomers, pharmaceutically acceptable salts and polymorphs wherein said compound described is a group of antisense molecules possessing immediate global cellular penetration due to their molecular structure and lipophilicity. The molecules are combinations of ethyl and methyl pyruvates. They induce riboswitch activity and reduce target RNA and nucleic acids such as HbA1c. They reduce inflammation and enhance energy production. These features improve therapeutic outcomes of diabetes, neuropathy and cellular aging. | 06-06-2013 |
20130195975 | IN VIVO USE OF WATER ABSORBENT POLYMERS - The subject invention is a method and material for removing fluid from the intestinal tract of a host and may be useful in treating animals or human patients suffering from fluid overload states. In one embodiment, the subject method involves ingesting an enterically coated non-systemic, non-toxic, non-digestible, water absorbing polymer which absorbs fluid while passing through the intestinal tract. The polymer is excreted in the feces wherein the polymer and absorbed fluid is removed from the body. Preferred polymers include super absorbent acrylic acid polymers, preferably provided in bead form. The polymers may include functional groups for selectively removing blood borne waste products, e.g. urea, from the G.I. tract. | 08-01-2013 |
20130202694 | Agent for use in the case of fructose intolerance - There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed. | 08-08-2013 |
20130202695 | Agent for use in the case of fructose intolerance - There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. | 08-08-2013 |
20130202696 | Agent for use in the case of fructose intolerance - There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. | 08-08-2013 |
20130216619 | PHARMACEUTICAL COMPOSITION OF ATORVASTATIN AND EZETIMIBE - The present invention relates to an oral pharmaceutical composition comprising: a) a core comprising atorvastatin or a pharmaceutically acceptable salt thereof and an alkalizing agent; b) an intermediate coating over the core; and c) an outer coating comprising ezetimibe. | 08-22-2013 |
20130230588 | CONTROLLED RELEASE COMPOSITIONS - An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract. | 09-05-2013 |
20130236541 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER - The present invention relates to a combination comprising a substance with inhibiting effect on the ileal bile acid transport system (I BAT) and at least one other active substance selected from an IBAT inhibitor; an enteroendocrine peptide or enhancer thereof; a dipeptidyl peptidase-IV inhibitor; a biguanidine; an incretin mimetic; a thiazolidinone; a PPAR agonist; a HMG Co-A reductase inhibitor; a bile acid binder; and a TGR5 receptor modulator; wherein the IBAT inhibitor compound and the at least one other active substance are administered simultaneously, sequentially or separately. | 09-12-2013 |
20130243855 | Modified coagulation factor IX polypeptides and use thereof for treatment - Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides. | 09-19-2013 |
20130273155 | Prebiotic Compositions for use with Probiotics to increase probiotic growth rate and activity - Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of | 10-17-2013 |
20130295173 | COMPOSITIONS OF STATINS AND OMEGA-3 FATTY ACIDS - The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms. | 11-07-2013 |
20130344142 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 12-26-2013 |
20140010872 | ORAL COMPLEX COMPOSITION COMPRISING OMEGA-3 FATTY ACID ESTER AND HMG-COA REDUCTASE INHIBITOR - An oral complex composition comprising omega-3 fatty acid esters and HMG-CoA reductase inhibitor, can effectively raise serum HDL level while reducing serum LDL and TG levels and can be used to treat hyperlipidemia owing to its good drug dissolution rate and storage stability with showing no delayed release behavior even after 6 months of accelerated storage. | 01-09-2014 |
20140030324 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-RELATED DISEASE - The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one ore more oxalate-reducing enzymes to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions. | 01-30-2014 |
20140072627 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS - A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided. | 03-13-2014 |
20140105974 | COMPOSITIONS FOR ENCAPSULATING BIOMATERIALS AND USES RELATED THERETO - This disclosure relates to compositions and methods for encapsulating biomaterials such as cells to prevent immune responses. In certain embodiments the disclosure relates to capsules comprising a cell or cells gelled in alginate coated with a layer that prevents migration of immune molecules to the cell surface and an outer capsule layer comprising non-immunogenic material optionally containing immunosuppressive agents. In certain embodiments, the cells are capable of generating insulin that emanates from the capsule. | 04-17-2014 |
20140105975 | FILM COATING FOR TABLETS AND CAPLETS - The present invention relates to novel coating compositions for application to solid dosage forms such as tablets or caplets, solid dosage forms coated with the composition, and methods of preparing said coating compositions. | 04-17-2014 |
20140112986 | PROLIPOSOMAL TESTOSTERONE FORMULATIONS - Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy. | 04-24-2014 |
20140141077 | COMPOSITION FOR USE IN TREATING AND PREVENTING INFLAMMATION RELATED DISORDER - The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (HA) or HA mixture, whereas the HA or the HA mixture as a delivery vehicle can be a formulation including at least two HAs having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), Crohn's Disease, irritable bowel syndrome (IBS), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis. | 05-22-2014 |
20140154315 | Hydrophobic Preparations - The present invention relates to preparations of substances in hydrophobic solvents in which they would not normally be soluble and to processes for obtaining these preparations. In particular, the invention relates to preparations of hydrophilic species in hydrophobic solvents such as oils. The use of these preparations as vaccines and in pharmaceutical compositions is also described. | 06-05-2014 |
20140199391 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND - The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety of applications of the formulations of the invention. The subject invention includes novel soluble forms and various formulations of flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations. | 07-17-2014 |
20140212485 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 07-31-2014 |
20140212486 | ISOMETHEPTENE ISOMER - The invention relates to a purified Isometheptene compound comprising the structure according to Formula (I), | 07-31-2014 |
20140234413 | CAGED PLATINUM NANOCLUSTERS FOR ANTICANCER CHEMOTHERAPEUTICS - A caged platinum nanocluster complex is disclosed. The complex comprises (a) an amine-terminated dendrimer; and (b) a platinum nanocluster comprising platinum oxides, the platinum nanocluster being confined inside of the amine-terminated dendrimer. The complex exhibits cytotoxicity to cancer cells. A double-caged platinum nanocluster complex is also disclosed, which comprises polyethylene glycol (PEG) coated on the surface of a dendrimer caged platinum nanocluster complex. The double-caged caged platinum nanocluster complex comprises pH-sensitive bonds on the surface thereof. Also disclosed are methods of preparing and using the same. | 08-21-2014 |
20140234414 | Novel Dosage Form - There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration. | 08-21-2014 |
20140242163 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 08-28-2014 |
20140242164 | COMPOSITION AND METHOD OF OBTAINING ORAL OR ENTERAL DOSAGE FORMS OF PHYTOCHEMICALS FROM POMEGRANATES - Nutraceutical compositions for improved administration of important phytochemicals from pomegranate to a human or animal. More particularly, enables oral or enteral dosage forms containing phytochemicals from pomegranate for administering on a routine basis. In at least one instance the natural contents of a pomegranate are encapsulated into a pill form or concentrated juice that provides for more efficient administration than eating a pomegranate but contains the same key ingredients present in the fruit. Enables the recipient to receive the benefits of the fruit but allows for the dosages to be taken in pill or concentrated juice form. Composition is chemically similar or equal to a natural pomegranate but is in a powder, pill or concentrated liquid form. | 08-28-2014 |
20140242165 | Biocompatible Carrier Containing A Bioadhesive Material - A biocompatible carrier for delivery of a therapeutic substance or an active agent is disclosed. The carrier contains a bioadhesive material allowing for increased residence time of the active agent at the treatment site. | 08-28-2014 |
20140248342 | Fe(III) 2,4-Dioxo-1-Carbonyl Complexes For Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anaemias - The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use in the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias. | 09-04-2014 |
20140248343 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE MORPHINE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 09-04-2014 |
20140248344 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE MORPHINE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 09-04-2014 |
20140271843 | Multi-Layer Hydrogel Capsules for Encapsulation of Cells and Cell Aggregates - Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject. | 09-18-2014 |
20140271844 | COMPOSITIONS CONTAINING NITRO FATTY ACIDS - Compositions, dietary supplement compositions, and topical compositions including activated fatty acids and methods for using activated fatty acids to treat a variety of diseases. | 09-18-2014 |
20140271845 | COATED SUBSTRATE COMPOSITIONS - Pharmaceutical compositions in unit dose form comprising a hollow substrate and one or more coatings on the hollow substrate, wherein at least one coating comprises at least one active pharmaceutical ingredient, and methods of making the same are provided. | 09-18-2014 |
20140271846 | GASTRORETENTIVE DOSAGE SYSTEM AND PROCESS OF PREPARATION THEREOF - The present invention relates to novel gastroretentive dosage systems, in particular, a floating capsule which releases the drug without any lag time and which remains buoyant for a sufficient period of time in the stomach. Further, the invention relates to the process of preparation thereof. | 09-18-2014 |
20140294951 | Oral formulations mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D - The invention provides pharmaceutical compositions, methods for the treatment of and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. RYGB, as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including T2D and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome. In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans. | 10-02-2014 |
20140308347 | CATIONIC ANTIBACTERIAL COMPOSITION - The present invention relates to compounds that are cationic vancomycin analogues and their compositions. Method of making the compounds and their use as medicament for the treatment of bacterial infection are also disclosed. | 10-16-2014 |
20140314843 | ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES - The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides. | 10-23-2014 |
20140314844 | ORAL COMPLEX FORMULATION COMPRISING OMEGA-3 FATTY ACID AND HMG-COA REDUCTASE INHIBITOR WITH IMPROVED STABILITY - The present invention relates to an oral complex formulation comprising omega-3 fatty acid or its derivatives encapsulated in a hard or soft capsule containing sorbitol and sorbitan, as well as an HMG-CoA reductase inhibitor. The formulation of the present invention comprising omega-3 fatty acid encapsulated with sorbitol and sorbitan provides better prevention related materials from being formed, leading to improved long-term storage stability. The oral complex formulation of the present invention also can raise the serum HDL-cholesterol level, while reducing both LDL-cholesterol and TG levels. The oral complex formulation of the present invention is useful for treatment of hyperlipidemia. | 10-23-2014 |
20140322316 | Optimal Colon Targeting Technology - The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value. | 10-30-2014 |
20140322317 | CONTROLLED RELEASE COMPOSITIONS - An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract. | 10-30-2014 |
20140328910 | INGESTION METHOD OF CREATINE COMPOSITION, CREATINE COMPOSITION FOR USING IN THE INGESTION METHOD, AND CREATINE-CONTAINING MEDICAMENT AND FOOD EACH PRODUCED USING THE CREATINE COMPOSITION - An ingestion method of creatine composition, taking orally the creatine composition with beverage, characterized in that, the creatine composition is taken orally by preparing creatine composition aqueous solution with dissolving the creatine composition over one minute into water heating at 80-100° C. and by mixing the creatine composition aqueous solution with the beverage having ordinary or cool temperature. | 11-06-2014 |
20140341987 | COLOUR CHANGING COMPOSITION IN O/W EMULSION FORM - A changing colour composition for caring for and/or making up keratin materials on the form of an O/W emulsion comprising, in a physiologically acceptable medium, at least a) microcapsules containing releasable colorant(s), said microcapsules comprising: —a core comprising one organic material, —at least one layered coating surrounding said core, the layered coating comprising at least one polymer, at least one colorant, and advantageously at least one lipid-based material, b) at least 5% by weight, more preferably at least 8% by weight and advantageously at least 10% by weight relative to the weight of the composition of an aqueous phase comprising water and at least one compound chosen from polyols, glycols C2-C8 monoalcohols and mixtures thereof, c) non entrapped Ti0 | 11-20-2014 |
20140356426 | TAMPER-RESISTANT DOSAGE FORM CONTAINING ONE OR MORE PARTICLES - The invention relates to a tamper-resistant pharmaceutical dosage form comprising one or more particles, wherein each of said one or more particles
| 12-04-2014 |
20140377345 | CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG - Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration. | 12-25-2014 |
20150024046 | ABUSE-PROOFED ORAL DOSAGE FORM - The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N. | 01-22-2015 |
20150050336 | Taste Masking System For Non-Plasticizing Drugs - The present invention relates to taste masking system, taste masked formulations, dosage forms made from those formulations and methods of making those formulations that involve dissolving or dispersing a pH dependent polymer and a non-plasticizing active pharmaceutical ingredient in a solvent, granulating using that material or forming layers over a solid support therewith. This can be followed with the use of a taste masking overcoating layer. | 02-19-2015 |
20150056276 | COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND VITAMIN D FOR PSORIASIS, AND METHODS AND USES THEREOF - The present disclosure relates to pharmaceutical compositions comprising omega-3 fatty acids and vitamin D for use in at least one of preventing and treating psoriasis, and to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with psoriasis. | 02-26-2015 |
20150064247 | ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE HYDROCODONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-05-2015 |
20150064248 | ABUSE RESISTANT FORMS OF EXTENDED RELEASE HYDROMORPHONE, METHOD OF USE AND METHOD OF MAKING - An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided. | 03-05-2015 |
20150071999 | Novel RNAi Molecule Delivery Platform Based on Single-siRNA and shRNA Nanocapsules - Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications. | 03-12-2015 |
20150072000 | METHOD FOR PRODUCING ENTERIC ALGINATE MICROCAPSULES VIA IONIC GELATION CONTAINING DICLOFENAC OR ONE OF THE SALTS THEREOF AND MULTIPARTICLED PHARMACEUTICAL COMPOSITION CONTAINING THEM - Method for producing enteric microcapsules without coating, containing diclofenac or one of the salts thereof with satisfactory anti-inflammatory activity and low gastric aggressiveness; and a pharmaceutical composition containing them. The method comprises a) preparing a mixture in water-ethanol with an alginate salt, adding diclofenac or one of the salts thereof previously diluted with a surfactant and sodium bicarbonate; b) adding the previous solution to a solution with a calcium salt; c) resuspending the microcapsules obtained and isolated in an aqueous solution of the alginate salt; and d) isolating, drying and sieving through 1000 and 250 micron meshes the microcapsules obtained; and selecting the fraction comprised between both meshes. The pharmaceutical composition can be an oral composition, tablets, chewable tablets, or a powder for suspension in water. | 03-12-2015 |
20150086627 | DOSAGE FORMS OF HALOFUGINONE AND METHODS OF USE - Oral and parenteral dosage forms comprising halofuginone, including enteric-coated solid oral dosage forms, subcutaneous dosage forms and intravenous dosage forms, for administration to subjects in need thereof, e.g., subjects having been identified with musculoskeletal disorders, fibrotic diseases, malaria, or cancer are described herein. | 03-26-2015 |
20150104507 | FORMULATION OF LACOSAMIDE - A modified release formulation of lacosamide. | 04-16-2015 |
20150118299 | Capsule Formulation - An object of the present invention is to provide a capsule formulation comprising a phosphonooxymethyl derivative of ravuconazole which suppresses delay in dissolution due to storage regardless of an encapsulated amount of the phosphonooxymethyl derivative of ravuconazole. The present invention provides a capsule formulation comprising an encapsulated material comprising {[(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyl dihydrogen phosphate or a pharmacologically acceptable salt thereof, or a solvate of any of the foregoing, and a capsule shell not comprising gelatin. | 04-30-2015 |
20150125522 | ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS - Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide. | 05-07-2015 |
20150132377 | MULTI-CAPSULE COMPOSITIONS - A capsule delivery system. The system has a first capsule containing a first capsule wall encapsulating a first active material and a second capsule containing a second capsule wall encapsulating a second active material. The first and second capsules differ in their wall materials, amounts of wall materials, ratios of wall materials, core modifiers, scavengers, active materials, curing temperatures, heating rates, curing times, or a combination thereof. Also provided is a consumer product containing this capsule delivery system. | 05-14-2015 |
20150140090 | ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION - A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect. | 05-21-2015 |
20150140091 | SOLID DISPERSION COMPRISING A HIGHLY SUBSTITUTED HYDROXYALKYL METHYLCELLULOSE - A solid dispersion comprising at least one active ingredient in at least one hydroxyalkyl methylcellulose having a DS of from 1.0 to 2.7 and an MS of from 0.40 to 1.30, wherein DS is the degree of substitution of methoxyl groups and MS is the molar substitution of hydroxyalkoxyl groups, can be produced by extrusion or spray-drying. | 05-21-2015 |
20150140092 | COATED DRUG DELIVERY FORMULATIONS - The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations. | 05-21-2015 |
20150290174 | PHARMACEUTICAL FORMULATIONS AND METHOD OF USING THE SAME FOR ALLEVIATING SYMPTOMS OF HANGOVER, STOMACH FLU OR MIGRAINE - Described herein are pharmaceutical formulations and dosage forms that include an analgesic agent, a nonsteroidal anti-inflammatory agent, a gastric acid production suppressant, and an anti-nauseant, which are capable of alleviating the symptoms of hangovers, stomach flu or migraine. | 10-15-2015 |
20150299689 | ENGINEERED TYROSINE AMMONIA LYASE - The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the engineered TAL polypeptides for therapeutic and industrial purposes. | 10-22-2015 |
20150306144 | PROBIOTIC RECOLONISATION THERAPY - The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of | 10-29-2015 |
20150306156 | PROBIOTIC RECOLONISATION THERAPY - The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic | 10-29-2015 |
20150313862 | "Pharmaceutical composition for reducing the trimethylamine N-oxide level" - The invention discloses the use of pharmaceutical compositions containing 3-(2,2,2-trimethylhydrazinium)propionate dihydrate and pharmaceutically acceptable salts thereof for trimethylamine N-oxide level decrease in a body. | 11-05-2015 |
20150335715 | METHODS AND COMPOSITIONS FOR TREATING NAFLD, HEPATIC STEATOSIS, AND SEQUELAE THEREOF - Provided herein are oral pharmaceutical compositions containing a GLP-1 analogue and/or insulin for treating and reducing the incidence of nonalcoholic fatty liver disease (NAFLD), hepatic steatosis, and sequelae thereof and methods of utilizing same. | 11-26-2015 |
20150352068 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS - The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a bipolar trans carotenoid, ii) a cyclodextrin, and iii) a coating. The invention also relates to preparation of such formulations and their uses. | 12-10-2015 |
20150359749 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE - The invention provides novel formulations of guanylate cyclase-C(“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative. | 12-17-2015 |
20150359750 | POSITIONING IMMEDIATE-RELEASE BIOADHESIVE AND APPLICATION THEREOF - Provided is a positioning immediate-release bioadhesive and relates to a medical device for preventing or/and treating diabetes, obesity, alcoholism, gastric and intestinal mucosal inflammation or/and ulcers and the like. The positioning immediate-release bioadhesive is prepared by preparing a biocompatible bioadhesive material into micro-particles, externally adding an immediate-release disintegrant, tabletting and then performing enteric or gastric coating; or performing enteric or gastric coating on the micro-particles; or filling into enteric-coated or gastric-coated hollow capsules; or directly tabletting the bioadhesive material, the immediate-release disintegrant and other additional agents and then performing enteric or gastric coating. After the positioning immediate-release bioadhesive is taken, the positioning immediate-release bioadhesive can realize positioning and immediate release, rapidly adhere to and cover the upper segment of duodenum and jejunum or/and gastric mucosa and weaken the absorption of the upper segment of duodenum and jejunum or/and stomach. The positioning immediate-release bioadhesive is orally administered, convenient to carry, convenient to store and convenient to use, and a patient using the positioning immediate-release bioadhesive does not need to go to a hospital, perform an operation or use endoscopy and further has no pain, thereby enhancing the compliance of a user and avoiding the complexity of the operation. | 12-17-2015 |
20150366920 | METHOD FOR PREVENTING AND/OR TREATING INFECTIONS, COLONISATIONS, OR ILLNESSES RELATED TO STAPHYLOCOCCUS AUREUS, PSEUDOMONAS AERUGINOSA, STREPTOCOCCUS PYOGENES, ENTEROCOCCUS FAECIUM, ENTEROBACTER CLOACAE, PROTEUS MIRABILIS, BACTEROIDES FRAGILIS, STAPHYLOCOCCUS EPIDERMIDIS, PROPIONIBACTERIUM ACNES, CANDIDA ALBICANS AND/OR MALASSEZIA FURFUR - The subject matter of the present invention is a bacterium or a mixture of bacteria having an antagonistic activity with respect to strains of | 12-24-2015 |
20150366970 | PHARMACEUTICAL LIPID COMPOSITIONS - The present invention relates to a particulate composition containing; a) 5 to 90% of at least one phosphatidyl choline component b) 5 to 90% of at least one diacyl glycerol component, at least one tocopherol, or mixtures thereof, and c) 1 to 40% of at least one non-ionic stabilising amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and where the composition contains particles of at least one non-lamellar phase structure or forms particles of at least one non-lamellar phase structure when contacted with an aqueous fluid. The invention additionally relates to pharmaceutical formulations containing such compositions, methods for their formation and methods of treatment comprising their administration. | 12-24-2015 |
20160022592 | TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTS - The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of | 01-28-2016 |
20160038514 | Adjunctive Therapy With 25-Hydroxyvitamin D and Articles Therefor - Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event. | 02-11-2016 |
20160120820 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR AND METHOD OF PREPARING THE SAME - A pharmaceutical composition, including: an active ingredient-loaded pellet core and a coating layer. The active ingredient of the pellet core is oseltamivir or a pharmaceutically acceptable salt thereof. The active ingredient accounts for between 10 and 40 wt. % of the total weight of the pharmaceutical composition. The coating layer includes a polyacrylic acid resin IV and accounts for between 1 and 50 wt. % of the total weight of the pharmaceutical composition. The pharmaceutical composition has a diameter of between 0.10 and 0.50 mm. | 05-05-2016 |
20160151345 | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARB- OXAMIDE, PREPARATION AND USES THEREOF | 06-02-2016 |
20160151346 | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARB- OXAMIDE, PREPARATION AND USES THEREOF | 06-02-2016 |
20160151429 | PROBIOTIC RECOLONISATION THERAPY | 06-02-2016 |
20160151431 | PROBIOTIC RECOLONISATION THERAPY | 06-02-2016 |
20160151432 | PROBIOTIC RECOLONISATION THERAPY | 06-02-2016 |
20160151433 | PROBIOTIC RECOLONISATION THERAPY | 06-02-2016 |
20160184242 | Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases - The present disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein. | 06-30-2016 |
20160193155 | PULSATILE-RELEASE DOSAGE FORM | 07-07-2016 |
20160199433 | Vegetarian Capsules Containing Supercritical Herbal Extracts | 07-14-2016 |
20160375047 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 12-29-2016 |
20160375067 | PROBIOTIC RECOLONISATION THERAPY - The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of | 12-29-2016 |
20180021354 | Adjunctive Therapy With 25-Hydroxyvitamin D and Articles Therefor | 01-25-2018 |
20190142757 | TAMPER-RESISTANT DOSAGE FORM CONTAINING ONE OR MORE PARTICLES | 05-16-2019 |
20190142769 | USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO SUPPRESS TUMOR METASTASES | 05-16-2019 |
20190142847 | Adjunctive Therapy with 25-Hydroxyvitamin D and Articles Therefor | 05-16-2019 |
20220134301 | PH-SENSITIVE CAPSULE AND RELEASE SYSTEM - A pH-sensitive release system comprising a capsule capable of releasing an agent in both low pH environments and high pH environments. The capsule encapsulates an agent and comprises at least two weak polyelectrolytes (e.g., PEI and PAA). The capsule responds to both low and high pH changes in the local environment by releasing the agent. The agent may include a corrosion inhibitor and may help prevent or ameliorate the effects of corrosion. | 05-05-2022 |